Loading...
XNAS
AEMD
Market cap529kUSD
Jul 09, Last price  
0.70USD
1D
0.14%
1Q
-67.97%
Jan 2017
-100.00%
Name

Aethlon Medical Inc

Chart & Performance

D1W1MN
XNAS:AEMD chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
41.01%
Rev. gr., 5y
%
Revenues
0k
000001,360,0001,230,0001,624,000762,417886,572392,073149,625229,625650,187659,104294,165574,245000
Net income
-7m
L-46.58%
-6,025,000-4,140,000-6,084,000-4,573,000-5,711,000-8,111,000-4,892,000-13,357,000-6,797,000-4,872,000-7,276,000-5,680,000-6,195,000-6,373,948-7,886,709-10,416,091-12,029,786-12,208,174-13,388,089-7,151,469
CFO
-7.00t
L+91,535,610.01%
-1,718,904-2,104,272-1,777,388-1,977,517-1,968,333-1,841,355-2,098,857-2,138,971-5,049,414-4,329,307-3,505,900-3,910,680-4,293,433-5,197,608-6,764,940-9,767,157-10,505,128-10,129,810-7,645,532-6,998,392,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
URL
https://www.aethlonmedical.com/
IPO date
Mar 09, 1994
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT